Abstract
Purpose
To evaluate adherence to European Society of Endocrinology guidelines and risk of renal complications in patients with chronic post-operative hypoparathyroidism (PO-HypoPT) treated with calcium and activated vitamin D metabolites.
Methods
We evaluated 90 adult patients (68 females and 22 males) with chronic (3 years) PO-HypoPT. Total albumin-corrected (Alb-Ca) and ionized serum calcium, phosphate, creatinine, PTH, and 24-h urinary calcium were measured; renal ultrasound was also performed. Healthy hospital employers (n = 142) were used as control.
Results
Complete data were available in 82 patients. Twenty-eight (34.1%) met four targets (Alb-Ca, phosphate, calcium phosphate product and 24-h urinary calcium), 36 (43.9%) three, 17 (20.7%) two, and 1 (1.2%) one. Thirteen (14.4%) had Alb-Ca value below and 18 (20.0%) above the target range and 54.9% 24-h urinary calcium above the upper normal limit. Seven (7.7%) has increased serum phosphate and none an increased calcium phosphate product. Eleven (12.2%) patients had eGFR < 60 mL/min × 1.73 m2. Nephrolithiasis was present in 27 (30%) patients. Compared with the controls, patients had lower Alb-Ca (8.9 ± 0.5 vs. 9.5 ± 0.3 mg/dL, P 0.0001) and a higher rate of kidney stones, mostly asymptomatic [27/90 (30%) vs 7/142 (5%), P < 0.0001, odd ratio 8.2 (3.4–19.9)]. Fifty-seven patients had ≥ four serum Ca2+ determinations during follow-up. Forty (70.2) patients had values within the target range in > 50% of cases, 18 in > 75%, and only 2 in 100%. Two patients never had values in the target range.
Conclusions
Treatment of chronic PO-HypoPT with calcium and activated vitamin D metabolites is suboptimal and associated with an increased risk of renal complications.
Similar content being viewed by others
References
Shoback D (2008) Clinical practice. Hypoparathyroidism. N Engl J Med 359(4):391–403. https://doi.org/10.1056/NEJMcp0803050 (359/4/391 [pii])
Clarke BL, Brown EM, Collins MT, Juppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101(6):2284–2299. https://doi.org/10.1210/jc.2015-3908
Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes T, Bouillon R (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101(6):2300–2312. https://doi.org/10.1210/jc.2015-3909
Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzullo L (2004) Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 28(3):271–276. https://doi.org/10.1007/s00268-003-6903-1
Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A (2015) Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg 102(4):359–367. https://doi.org/10.1002/bjs.9676
Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM, European Society of E (2015) European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173(2):G1–20. https://doi.org/10.1530/EJE-15-0628 (173/2/G1 [pii])
Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101(6):2273–2283. https://doi.org/10.1210/jc.2015-3907
Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97(12):4507–4514. https://doi.org/10.1210/jc.2012-1808 (jc.2012-1808 [pii])
Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28(11):2277–2285. https://doi.org/10.1002/jbmr.1979
Levey AS, Inker LA (2017) Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther 102(3):405–419. https://doi.org/10.1002/cpt.729
Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146(2):215–222 (146215 [pii])
Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP (2008) Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23(12):2018–2024. https://doi.org/10.1359/jbmr.080803
Croppi E, Ferraro PM, Taddei L, Gambaro G, Group GEAFS (2012) Prevalence of renal stones in an Italian urban population: a general practice-based study. Urol Res 40(5):517–522. https://doi.org/10.1007/s00240-012-0477-z
Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP (2016) Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab 101(7):2742–2750. https://doi.org/10.1210/jc.2015-4135
Acknowledgements
The authors gratefully thank Dr. Giovanni Guglielmi and Dr. Irene Donato (U.O. Medicina Preventiva, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) for their collaboration in the evaluation of the control subjects.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Claudio Marcocci has received honorary and travel Grants from Shire. The other authors have no conflict of interest.
Ethical approval
The authors confirm that this retrospective work was performed in compliance with Ethical Standards and according to Institutional Review Board standards.
Informed consent
Informed consent was obtained from all participants.
Rights and permissions
About this article
Cite this article
Meola, A., Vignali, E., Matrone, A. et al. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 41, 1221–1226 (2018). https://doi.org/10.1007/s40618-018-0857-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-018-0857-5